Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2017 16:02 ET | Source: FibroGen, Inc

FibroGen Reports Third Quarter 2017 Financial Results

Roxadustat NDA Filing Accepted for CFDA Review; Positive Pamrevlumab Phase 2 IPF Results ReportedConference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time ...
October 30, 2017 20:00 ET | Source: FibroGen, Inc

FibroGen to Report Third Quarter Financial Results on Wednesday, November 8, 2017

SAN FRANCISCO, Oct. 30, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it will report financial results for the third quarter...
October 18, 2017 07:00 ET | Source: FibroGen, Inc

FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated With Dialysis and Non-Dialysis Chronic Kidney Disease (CKD)

SAN FRANCISCO, Oct. 18, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical Technology Development Co., Ltd....
September 19, 2017 16:35 ET | Source: FibroGen, Inc.

FibroGen Appoints Gerald Lema to Board of Directors

SAN FRANCISCO, Sept. 19, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that Gerald Lema, former President of Asia Pacific at...
September 13, 2017 07:00 ET | Source: FibroGen, Inc.

Fibrogen Presents Latest Data From Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at European Respiratory Society (ERS) International Congress 2017

MILAN, Italy, Sept. 13, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, announced today positive results from the company’s Phase 2b randomized,...
September 05, 2017 16:05 ET | Source: FibroGen, Inc.

FibroGen Announces Pamrevlumab Oral and Poster Presentations at European Respiratory Society International Congress 2017

SAN FRANCISCO, Sept. 05, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced oral and poster presentations on pamrevlumab, an anti-CTGF...
August 15, 2017 23:31 ET | Source: FibroGen, Inc.

FibroGen, Inc. Announces Pricing of Follow-On Offering of Common Stock

SAN FRANCISCO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it has priced an underwritten follow-on offering, which...
August 14, 2017 16:26 ET | Source: FibroGen, Inc.

FibroGen, Inc. Announces Proposed Follow-On Offering of Common Stock

SAN FRANCISCO, Aug. 14, 2017 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, today announced that it intends to offer and sell up to $300 million of its...
August 07, 2017 16:50 ET | Source: FibroGen, Inc.

FibroGen Announces Positive Topline Results from Phase 2 Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis

Meets Primary Endpoint with Statistical Significance Management to discuss results on today’s quarterly financial results conference call SAN FRANCISCO, Aug. 07, 2017 (GLOBE NEWSWIRE) -- FibroGen,...
August 07, 2017 16:38 ET | Source: FibroGen, Inc.

FibroGen Reports Second Quarter 2017 Financial Results

Company Announces Positive Topline Results from Phase 2 Study in IPF Conference Call and Webcast to be Held Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time SAN FRANCISCO, Aug. 07, 2017 ...